Denture Cream Lawsuit – Zinc Poisoning Symptoms

Denture Cream Lawsuit – Zinc Poisoning Symptoms: "It has increasingly been reported that the denture cream ingredient zinc is associated with neurological symptoms including neuropathy in denture wearers. The recommended daily allowance of zinc is 8 mg for women and 11 mg for men. According to the Institute of Medicine of the National Academies the largest daily tolerable zinc intake is 40 mg.

Litigation Law - Guide to Litigation Law

Litigation Law - Guide to Litigation Law: "Litigation Law covers the process of bringing and pursuing a lawsuit, and encompasses the entire procedure. A lawsuit is a case or controversy authorized by law, to be decided in a court of justice, brought by one person or entity against another person or entity for the purpose of enforcing a right or redressing a grievance.

Maritime Injury Attorney

Maritime Injury Attorney: "If you have been injured while working offshore in California, you may have special rights for damage recovery under maritime law. We may also be able to provide legal representation and help you recover damages after being exposed to a toxic substance offshore. Every case is unique, so it is important to work with an experienced California injury lawyer for the best result. We can help you determine if your employer is liable for your injuries and if you are entitled to compensation under the Jones Act.

DePuy Hip Replacements Recalled Due to Failure

DePuy Hip Replacements Recalled Due to Failure, by Texas Personal Injury Lawyer: "On August 26, 2010 DePuy Orthopaedics Inc. announced a recall of 93,000 hip replacement systems due to a higher than expected number of people experiencing pain and other symptoms so severe that a second hip replacement surgery became necessary.

Essentially, DuPuy has acknowledged their hip implants are defective products. Since that time, the Texas DePuy Hip Replacement Recall Lawyers at Watts Guerra Craft have been searching for answers and solutions for their clients. Some of the symptoms of a failing DePuy ASR hip implant are loosening detachment of the implant, dislocation of the implant components or fracture of the bone around the implant. The ASR Hip Replacement System was approved for use in 2005 with complaints starting around 2007, where there were approximately 100. The number of reported DePuy hip replacement problems had doubled by 2008 and tripled by 2009. Major newspapers such as the The New York Times has published multiple articles about the problems and potential for more widespread problems for persons with these implants, practically forecasting the DePuy hip recall."

Birth Defects and Congenital Anomalies

Birth Defects and Congenital Anomalies: "What is a birth defect?

A 'birth defect' is a health problem or physical change, present in a baby at the time he/she is born. Birth defects may be very mild where the baby looks and acts like any other baby, or birth defects may be very severe(you can immediately tell there is a health problem present). Some of the severe birth defects can be life threatening, in which case a baby may only live a few months or may die at a young age (in their teens, for example).

Stage Information for Extrahepatic Bile Duct Cancer

Stage Information for Extrahepatic Bile Duct Cancer: "Note: The American Joint Committee on Cancer has recently published a new edition of the AJCC Cancer Staging Manual, which includes revisions to the staging for this disease. The PDQ Adult Treatment Editorial Board, which is responsible for maintaining this summary, is currently reviewing the new staging to determine the changes that need to be made in the summary. In addition to updating this Stage Information section, additional changes may need to be made to other parts of this summary to ensure that it is up-to-date. The changes will be made as soon as possible.

Note: Some citations in the text of this section are followed by a level of evidence. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more information.)

From a clinical and practical point of view, extrahepatic bile duct cancers can be considered to be localized (resectable) or unresectable. This has obvious prognostic importance.

Localized extrahepatic bile duct cancer

Patients with localized extrahepatic bile duct cancer have cancer that can be completely removed by the surgeon. These patients represent a very small minority of cases of bile duct cancer and usually are those with a lesion of the distal common bile duct where 5-year survival rate of 25% may be achieved. Extended resections of hepatic duct bifurcation tumors (Klatskin tumors) to include adjacent liver, either by lobectomy or removal of portions of segments 4 and 5 of the liver, may be performed. There has been no randomized trial of adjuvant therapy for patients with localized disease. Radiation therapy (external-beam radiation with or without brachytherapy), however, has been reported to improve local control.[1,2][Level of evidence: 3iiiDiii]"

Early Communication about an Ongoing Safety Review Orlistat (marketed as Alli and Xenical)

Early Communication about an Ongoing Safety Review Orlistat (marketed as Alli and Xenical): "FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and as an over-the-counter (OTC) product, Alli.

Xenical (orlistat 120mg) was approved as a prescription product by FDA in 1999 for obesity management in conjunction with a reduced caloric diet, and to reduce the risk of regaining weight after prior weight loss. In 2007, Alli (orlistat 60mg) was approved for OTC use for weight loss in overweight adults, 18 years and older, in conjunction with a reduced-calorie and low-fat diet. Currently, orlistat is approved for marketing in approximately 100 countries. In January 2009, a nonprescription version of orlistat was approved for sale in the European Union.

Between 1999 and October 2008, 32 reports of serious liver injury, including 6 cases of liver failure, in patients using orlistat were submitted to FDA’s Adverse Event Reporting System. Thirty of the 32 reports occurred outside the United States. The most commonly reported adverse events described in the 32 reports of serious liver injury were jaundice (yellowing of the skin or whites of the eyes), weakness, and abdominal pain. Hospitalization was reported in 27 of the 32 cases.

In addition to the 32 reported cases, this issue was discussed at the CDER Drug Safety Oversight Board in April 2009, and FDA is reviewing other data on suspected cases of liver injury submitted by the manufacturers of orlistat. FDA’s analysis of these data is ongoing and no definite association between liver injury and orlistat has been established at this time.

FDA is not advising healthcare professionals to change their prescribing practices with orlistat. Consumers currently taking Xenical should continue to take it as prescribed and those using over-the-counter Alli should continue to use the product as directed.

Consumers should consult their health care professional if they are experiencing symptoms possibly associated with the use of orlistat and development of liver injury, particularly weakness or fatigue, fever, jaundice or brown urine. Other symptoms may include abdominal pain, nausea, vomiting, light-colored stools, itching, or loss of appetite.

FDA urges both healthcare professionals and consumers to report side effects from the use of orlistat (Alli and Xenical) to FDA's MedWatch Adverse Event Reporting program using the information at the bottom of the page.

This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs. FDA will communicate its findings to the public as soon as its review of orlistat is complete."

DePuy Hip Replacements Recalled Due to Failure, by Texas Personal Injury Lawyer

DePuy Hip Replacements Recalled Due to Failure, by Texas Personal Injury Lawyer: "On August 26, 2010 DePuy Orthopaedics Inc. announced a recall of 93,000 hip replacement systems due to a higher than expected number of people experiencing pain and other symptoms so severe that a second hip replacement surgery became necessary.

Essentially, DuPuy has acknowledged their hip implants are defective products. Since that time, the Texas DePuy Hip Replacement Recall Lawyers at Watts Guerra Craft have been searching for answers and solutions for their clients. Some of the symptoms of a failing DePuy ASR hip implant are loosening detachment of the implant, dislocation of the implant components or fracture of the bone around the implant. The ASR Hip Replacement System was approved for use in 2005 with complaints starting around 2007, where there were approximately 100. The number of reported DePuy hip replacement problems had doubled by 2008 and tripled by 2009. Major newspapers such as the The New York Times has published multiple articles about the problems and potential for more widespread problems for persons with these implants, practically forecasting the DePuy hip recall."

DePuy ASR Implant Case Evaluations

DePuy ASR Implant Case Evaluations: "If you have experienced serious complications as a result of a hip replacement surgery involving a DePuy ASR device, it is important to know your legal options. Please call 800-452-8602 or fill out a form on this page for a complimentary case evaluation.

You will also receive additional information about the hundreds of lawsuits currently being filed against DePuy Orthopaedics and how you may be able to obtain compensation."

DePuy ASR Hip Lawsuit

Complications involving the DePuy ASR XL Acetabular System total hip replacement and ASR Hip Resurfacing System have prompted hundreds of patients to file lawsuits against DePuy Orthopaedics, the division of Johnson & Johnson that manufactures the hip devices. Patients are seeking compensation for medical bills and additional expenses associated with the hip devices following the recall of the products in August 2010.

All recipients of the DePuy ASR Hip Implant are entitled to legal compensation for their current and future health issues. For additional information about your legal options, please call 1-800-471-8602 or fill out the form on this page.

Depuy Hip Recall Lawsuit

Depuy Hip Recall Lawsuit: "Vanderhyde and Associates Law Firm is helping people who have been injured by Depuy Hip Replacement Parts. We are currently accepting DePuy Hip Recall Lawsuit cases nationwide. If you or someone you know has been injured by Depuy APR hip replacement parts, please contact our law firm for a free, no obligation consultation. Call Toll Free 1-866-777-2557 or fill our online contact form and a Depuy Hip Recall Attorney will get back to you as soon as possible."

Implant Alternatives: Mini Dental Implants

Implant Alternatives: Mini Dental Implants: "Narrower implants may be used for small teeth and incisors. Also, a narrower implant may best serve patients who require stabilization of lower jaw dentures, pre-molar teeth, or a missing tooth that was located in a narrow area. A small number of narrower implants are FDA-approved for the purpose of prosthesis stabilization, including the mini dental implant. Only certain dentists may perform this procedure.